Benzinga | Nov 9, 2021 05:34PM EST

ChemoCentryx Q3 EPS $(0.32) Beats $(0.45) Estimate, Sales $17.74M Beat $13.48M Estimate

ChemoCentryx (NASDAQ:CCXI) reported quarterly losses of $(0.32) per share which beat the analyst consensus estimate of $(0.45) by 28.89 percent. This is a 8.57 percent increase over losses of $(0.35) per share from the same period last year. The company reported quarterly sales of $17.74 million which beat the analyst consensus estimate of $13.48 million by 31.62 percent. This is a 248.93 percent increase over sales of $5.08 million the same period last year.